New paradigm in the treatment of myositis-associated interstitial lung disease

Expert Rev Respir Med. 2023 May;17(5):397-411. doi: 10.1080/17476348.2023.2215433. Epub 2023 May 24.


Introduction: Interstitial lung disease (ILD) is the leading cause of mortality in idiopathic inflammatory myopathies or myositis. Clinical characteristics, including the course of ILD, rate of progression, radiological and pathohistological morphologies, extent and distribution of inflammation and fibrosis, responses to treatment, recurrence rate, and prognosis, are highly variable among myositis patients. A standard practice for ILD management in myositis patients has not yet been established.

Areas covered: Recent studies have demonstrated the stratification of patients with myositis-associated ILD into more homogeneous groups based on the disease behavior and myositis-specific autoantibody (MSA) profile, leading to better prognoses and prevention of the burden of organ damage. This review introduces a new paradigm in the management of myositis-associated ILD based on research findings from relevant literature selected by a search of PubMed as of January 2023, as well as expert opinions.

Expert opinion: Managing strategies for myositis-associated ILD are being established to stratify patients based on the severity of ILD and the prediction of prognosis based on the disease behavior and MSA profile. The development of a precision medicine treatment approach will provide benefits to all relevant communities.

Keywords: Disease behavior; idiopathic inflammatory myopathy; interstitial lung disease; myositis-specific autoantibody; precision medicine; risk prediction model.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Autoantibodies
  • Humans
  • Lung Diseases, Interstitial* / drug therapy
  • Myositis* / complications
  • Prognosis
  • Retrospective Studies


  • Autoantibodies